The advantage of proton therapy over conventional radiotherapy is enormous, with many clinical advantages. In this review, we summarized the important literature in the advantages of Proton Therapy in Non-small Cell Lung Cancers.
Get full access to this article
View all access options for this article.
References
1.
The National Association for Proton Therapy. www.proton-therapy.org/backgrou.htm. 2013 Feb 10.
KesarwalaAH, GroverS, RenganR. The role of particle beam therapy in a trimodality approach to locally advanced non-small cell lung cancer. Thorac Cancer, 2012Epub Ahead of Print10.1111/j.1759-7714.2012.00174.x
8.
CalugaruV, NaurayeC, NoelGet al.Radiobiological characterization of two therapeutic proton beams with different initial energy spectra used at the Institut Curie Proton Therapy Center in Orsay. Int J Radiat Oncol Biol Phys, 2011; 81:1136.
NicholsRCJr., HuhSH, HendersonRHet al.Selective nodal irradiation of regionally advanced non-small-cell lung cancer with proton therapy and IMRT: A dosimetric comparison. Thorac Cancer, 2012; 3:169.
11.
ICRU. International commission on radiation units, measurements report 78: Prescribing, recording, reporting proton-beam therapy (ICRU report 78)J ICRU, 2007; 7:1–210.
12.
ShiW, NicholsRC, FlampouriSet al.Proton-based chemoradiation for synchronous bilateral non-small-cell lung cancers: A case report. Thorac Cancer, 2012Epub Ahead of Print10.1111/j.1759-7714.2012.00141.x
13.
PaganettiH. Significance and implementation of RBE variations in proton beam therapy. Technol Cancer Res Treat, 2003; 2:413.
14.
LomaxAJ, PedroniE, RutzHet al.The clinical potential of intensity modulated proton therapy. Z Med Phys, 2004; 14:147.
15.
LiuW, ZhangX, LiYet al.Robust optimization of intensity modulated proton therapy. Med Phys, 2012; 39:1079.
16.
ChenW, UnkelbachJ, TrofimovAet al.Including robustness in multi-criteria optimization for intensity-modulated proton therapy. Phys Med Biol, 2012; 57:591.
17.
Pijls-JohannesmaM, GruttersJP, VerhaegenFet al.Do we have enough evidence to implement particle therapy as standard treatment in lung cancer? A systematic literature review. Oncologist, 2010; 15:93.
18.
ArriagadaR, Le ChevalierT, QuoixEet al.ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: A randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCLCC (Federation Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists. Int J Radiat Oncol Biol Phys, 1991; 20:1183.
19.
MartelMK, Ten HakenRK, HazukaMBet al.Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer, 1999; 24:31.
20.
LeeCH, TaitD, NahumAEet al.Comparison of proton therapy and conformal X-ray therapy in non-small cell lung cancer (NSCLC)Br J Radiol, 1999; 72:1078.
21.
ChangJY, ZhangX, WangXet al.Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in stage I or stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 2006; 65:1087.
ShioyamaY, TokuuyeK, OkumuraTet al.Clinical evaluation of proton radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 2003; 56:7.
24.
BushDA, DunbarRD, BonnetRet al.Pulmonary injury from proton and conventional radiotherapy as revealed by CT. AJR Am J Roentgenol, 1999; 172:735.
25.
NakayamaH, SugaharaS, TokitaMet al.Proton beam therapy for patients with medically inoperable stage I non-small-cell lung cancer at the university of tsukuba. Int J Radiat Oncol Biol Phys, 2010; 78:467.
26.
IwataH, MurakamiM, DemizuYet al.High-dose proton therapy and carbon-ion therapy for stage I nonsmall cell lung cancer. Cancer, 2010; 116:2476.
27.
BushDA, SlaterJD, ShinBBet al.Hypofractionated proton beam radiotherapy for stage I lung cancer. Chest, 2004; 126:1198.
28.
HataM, TokuuyeK, KageiKet al.Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: Preliminary results of a phase I/II clinical study. Int J Radiat Oncol Biol Phys, 2007; 68:786.
29.
GruttersJP, KesselsAG, Pijls-JohannesmaMet al.Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: A meta-analysis. Radiother Oncol, 2010; 95:32.
30.
TerakedisB, SauseW. Radiation dose escalation in stage III non-small-cell lung cancer. Front Oncol, 2011; 1:47.
31.
YoonM. Development and current status of proton therapy for lung cancer in Korea. Thorac Cancer, 2012; 3:1.
32.
ZhangX, LiY, PanXet al.Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: A virtual clinical study. Int J Radiat Oncol Biol Phys, 2010; 77:357.
33.
ChangJY, CoxJD. Improving radiation conformality in the treatment of non-small cell lung cancer. Semin Radiat Oncol, 2010; 20:171.
34.
NicholsRC, HuhSN, HendersonRHet al.Proton radiation therapy offers reduced normal lung and bone marrow exposure for patients receiving dose-escalated radiation therapy for unresectable stage III non-small-cell lung cancer: A dosimetric study. Clin Lung Cancer, 2011; 12:252.
